Negio Therapeutics

  •    Drug discovery programme for a new target in oncology

Logo Theratrame c

  • AI-driven drug discovery for small molecules targeting tRNA epitranscriptomics in cancer. More info.
Neuvasq v2
  • Drug discovery to restore blood-brain barrier function in acute neurological disorders and neurodegenerative diseases. More info.
Santero logo 2
  • Antibiotics discovery to fight multidrug-resistant pathogens.  More info.
Logo Gepeceron
  • Drug discovery for small molecules targeting selected G protein-coupled receptors in solid tumors and inflammatory diseases.
Logo Chromacure jpeg
  • Drug discovery for small molecule inhibitors of novel targets in tumor initiation and cancer progression.



Picture1 circle
  • The partnership established in 2013 between Pierre Coulie & Sophie Lucas (WEL Research Institute - UCLouvain) and ArGenX led to the development of a humanized monoclonal antibody inhibitor of GARP, a novel immuno-oncology target, which is now in clinical development at AbbVie (ABBV-151). More info.
Picture2 circle
  • A joined university-company group was established in 2020 between Kaneka, its Walloon subsidiary Kaneka Eurogentec and the laboratory of Jean-François Collet (WEL Research Institute – UCLouvain) to develop optimized bacterial strains for the production of biomedicines. More info.


Downstream translation projects

  • The iCone (iPSC-derived Cortical neurons) consortium was established in 2016 between the laboratories of Pierre Vanderhaeghen (WEL Research Institute - ULB) and Philippe Hubert (U Liège) and the companies MaSTherCell and Ncardia. The project aimed at developing highly functional human cortical neurons from stem cells to provide a novel platform bridging traditional laboratory and clinical testing in patients. In 2019, the consortium reached a turning point and entered into a large-scale production phase using bioreactors. More info.
  • The CiclibTest project between Pierre Roger (WEL Research Institute – ULB) and OncoDNA was funded in 2017 by a WALInnov grant  to develop a diagnostic to stratify cancer patients for treatment with CDK4/6 inhibitors. More info.
modifié le 24/04/2024

Partager cette page